Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Human Papillomavirus | Research

Prevalence of genital high-risk human papillomavirus infections and associated factors among women living with human immunodeficiency virus in Uganda

Authors: Harriet Nakigozi, Rawlance Ndejjo, William Bazeyo, Annet Nabaggala, Caroline Achola, Moses Iga, Simeon Kalyesubula, Ben Kanamwangi, Gerald Mutungi, Charles Batte, David Mukunya, Lawrence Sserwanga, Godfrey Gemageine, Charles Akiya Oyoo, Susan Nabadda

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Women living with HIV are at risk for cervical dysplasia and cancer worldwide. In 2015, the World Health Organization (WHO) recommended that testing for high-risk HPV (hrHPV) infection be incorporated into cervical cancer screening programs using molecular nucleic acid tests (NATs) but this has not previously been done in Uganda. The country’s coverage for Human Papilloma Virus (HPV) screening remains low at less than 10% for women aged 25–49 years. This study determined the genital prevalence of hrHPV infection and the associated factors among women living with HIV in Uganda.

Methods

A descriptive cross-sectional study was conducted in 15 selected health facilities among participants who were on Antiretroviral therapy (ART). Participants who consented to participate were instructed on how to collect their own high vaginal swabs using a cervical brush for HPV molecular testing (HPV DNA or HPV RNA) and their demographics data was collected using a standard questionnaire. Laboratory diagnosis for HPV molecular testing was done using Gene xpert machines and Hologic Aptima Machine. Modified Poisson regression analysis was conducted to determine the associated factors.

Results

This study involved 5856 HIV positive participants on ART. A total of 2006 out of 5856 (34.3%) participants had high risk HPV infections. HPV infections by genotypes were: HPV16 317(15.8%), HPV 18/45 308 (15.4%) and other high-risk HPV 1381 (68.8%). The independent factors associated with all hrHPV were parity, education level, having more than one partner, and engaging in early sex. Smoking was associated with HPV 16, HPV 18/45 and other hrHPV. Age was associated with all hrHPV, marital status with HPV 16, and occupation with HPV 16.

Conclusions

The prevalence of genital high-risk HPV infections among HIV positive women attending ART clinics in public facilities in Uganda was high. Other hrHPV genotype was the commonest compared to 18/45 and HPV 16. The integration of cervical cancer screening in ART programmes remains paramount to support the early detection of cervical cancer and Non-invasive self-collected urine and vaginal sampling for cervical cancer screening present an opportunity.
Literature
2.
go back to reference Dreyer G. Clinical implications of the interaction between HPV and HIV infections. Best Pract Res Clin Obstet Gynecol. 2018;47:95–106.CrossRef Dreyer G. Clinical implications of the interaction between HPV and HIV infections. Best Pract Res Clin Obstet Gynecol. 2018;47:95–106.CrossRef
3.
go back to reference Nakisige C, Schwartz M, Ndira AO. Cervical cancer screening and treatment in Uganda. Gynecologic Oncol Rep. 2017;20:37–40.CrossRef Nakisige C, Schwartz M, Ndira AO. Cervical cancer screening and treatment in Uganda. Gynecologic Oncol Rep. 2017;20:37–40.CrossRef
4.
go back to reference Nakisige C, et al. Integrated cervical cancer screening in Mayuge District Uganda (ASPIRE Mayuge): a pragmatic sequential cluster randomized trial protocol. BMC Public Health. 2020;20(1):1–13.CrossRef Nakisige C, et al. Integrated cervical cancer screening in Mayuge District Uganda (ASPIRE Mayuge): a pragmatic sequential cluster randomized trial protocol. BMC Public Health. 2020;20(1):1–13.CrossRef
5.
go back to reference Zhao M, et al. Global, regional, and national burden of cervical cancer for 195 countries and territories, 2007–2017: findings from the global burden of Disease Study 2017. BMC Womens Health. 2021;21(1):1–13.CrossRef Zhao M, et al. Global, regional, and national burden of cervical cancer for 195 countries and territories, 2007–2017: findings from the global burden of Disease Study 2017. BMC Womens Health. 2021;21(1):1–13.CrossRef
6.
go back to reference Sung H, Ferlay J, Siegel RL. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries 2021. 71(3): p. 209–249. Sung H, Ferlay J, Siegel RL. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries 2021. 71(3): p. 209–249.
7.
go back to reference Banura C, et al. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: a systematic review. Infect Agents cancer. 2011;6(1):1–12.CrossRef Banura C, et al. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: a systematic review. Infect Agents cancer. 2011;6(1):1–12.CrossRef
8.
go back to reference PRESCRIP-TEC. PRESCRIP-TEC Project in Uganda 2020/21. PRESCRIP-TEC. PRESCRIP-TEC Project in Uganda 2020/21.
9.
go back to reference MOH-Uganda. Ministry of Health HIV prevalence report in Uganda 2014. MOH-Uganda. Ministry of Health HIV prevalence report in Uganda 2014.
10.
go back to reference Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.CrossRef
11.
12.
go back to reference Taube JM, et al. Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid‐based pap preparation. Diagn Cytopathol. 2010;38(8):555–63.CrossRefPubMed Taube JM, et al. Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid‐based pap preparation. Diagn Cytopathol. 2010;38(8):555–63.CrossRefPubMed
13.
go back to reference Singh AS, Masuku MB. Sampling techniques & determination of sample size in applied statistics research: an overview. Int J Econ Commer Manage. 2014;2(11):1–22. Singh AS, Masuku MB. Sampling techniques & determination of sample size in applied statistics research: an overview. Int J Econ Commer Manage. 2014;2(11):1–22.
14.
go back to reference Nang DW, et al. Prevalence of high-risk human papillomavirus infection and associated factors among women of reproductive age attending a rural teaching hospital in western Uganda. BMC Womens Health. 2023;23(1):209.CrossRefPubMedPubMedCentral Nang DW, et al. Prevalence of high-risk human papillomavirus infection and associated factors among women of reproductive age attending a rural teaching hospital in western Uganda. BMC Womens Health. 2023;23(1):209.CrossRefPubMedPubMedCentral
15.
go back to reference Saidu R, et al. Performance of Xpert HPV on Self-collected vaginal samples for Cervical Cancer Screening among women in South Africa. J Low Genit Tract Dis. 2021;25(1):15–21.CrossRefPubMed Saidu R, et al. Performance of Xpert HPV on Self-collected vaginal samples for Cervical Cancer Screening among women in South Africa. J Low Genit Tract Dis. 2021;25(1):15–21.CrossRefPubMed
16.
17.
go back to reference Haedicke J, Iftner T. A review of the clinical performance of the Aptima HPV assay. J Clin Virol. 2016;76:S40–8.CrossRefPubMed Haedicke J, Iftner T. A review of the clinical performance of the Aptima HPV assay. J Clin Virol. 2016;76:S40–8.CrossRefPubMed
18.
go back to reference Gormley JP, et al. A simplified molecular method to detect high-risk HPV using the Aptima HPV assay on head and neck FNA smears. Cancer Cytopathol. 2023;131(3):171–8.CrossRefPubMed Gormley JP, et al. A simplified molecular method to detect high-risk HPV using the Aptima HPV assay on head and neck FNA smears. Cancer Cytopathol. 2023;131(3):171–8.CrossRefPubMed
20.
go back to reference Tiiti T. Human papillomavirus testing using self-collected cervicovaginal samples versus doctor/nurse-collected samples for cervical cancer screening in women attending gynecology clinics at a tertiary hospital in Pretoria. South Africa. University of Antwerp; 2023. Tiiti T. Human papillomavirus testing using self-collected cervicovaginal samples versus doctor/nurse-collected samples for cervical cancer screening in women attending gynecology clinics at a tertiary hospital in Pretoria. South Africa. University of Antwerp; 2023.
21.
go back to reference Panther T. Aptima HPV 16 18/45 Genotype Assay Panther T. Aptima HPV 16 18/45 Genotype Assay
22.
go back to reference Adebamowo SN, et al. Persistent low-risk and high-risk human papillomavirus infections of the uterine cervix in HIV-negative and HIV-positive women. Front Public Health. 2017;5:178.CrossRefPubMedPubMedCentral Adebamowo SN, et al. Persistent low-risk and high-risk human papillomavirus infections of the uterine cervix in HIV-negative and HIV-positive women. Front Public Health. 2017;5:178.CrossRefPubMedPubMedCentral
24.
go back to reference Yaya I, et al. Heterogeneity in the prevalence of high-risk human papillomavirus infection in human immunodeficiency virus-negative and human immunodeficiency virus-positive men who have sex with men in West Africa. Clin Infect Dis. 2021;73(12):2184–92.CrossRefPubMed Yaya I, et al. Heterogeneity in the prevalence of high-risk human papillomavirus infection in human immunodeficiency virus-negative and human immunodeficiency virus-positive men who have sex with men in West Africa. Clin Infect Dis. 2021;73(12):2184–92.CrossRefPubMed
25.
go back to reference Zhao P, et al. Prevalence and genotype distribution of human papillomavirus infection among women in northeastern Guangdong Province of China. BMC Infect Dis. 2018;18(1):1–8.CrossRef Zhao P, et al. Prevalence and genotype distribution of human papillomavirus infection among women in northeastern Guangdong Province of China. BMC Infect Dis. 2018;18(1):1–8.CrossRef
26.
go back to reference Walboomers JM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.CrossRefPubMed Walboomers JM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.CrossRefPubMed
27.
go back to reference Denslow SA, et al. Incidence and progression of cervical lesions in women with HIV: a systematic global review. Int J STD AIDS. 2014;25(3):163–77.CrossRefPubMed Denslow SA, et al. Incidence and progression of cervical lesions in women with HIV: a systematic global review. Int J STD AIDS. 2014;25(3):163–77.CrossRefPubMed
28.
go back to reference Jeronimo J, et al. A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer. Int J Gynecol Cancer. 2014;24(3):576–85.CrossRefPubMedPubMedCentral Jeronimo J, et al. A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer. Int J Gynecol Cancer. 2014;24(3):576–85.CrossRefPubMedPubMedCentral
29.
go back to reference Ermel A, et al. A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women. BMC Infect Dis. 2019;19:1–8.CrossRef Ermel A, et al. A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women. BMC Infect Dis. 2019;19:1–8.CrossRef
30.
go back to reference Adams AR et al. Cervical human papillomavirus prevalence, genotypes, and associated risk factors among female sex workers in Greater Accra, Ghana Journal of Oncology, 2019. 2019. Adams AR et al. Cervical human papillomavirus prevalence, genotypes, and associated risk factors among female sex workers in Greater Accra, Ghana Journal of Oncology, 2019. 2019.
31.
go back to reference Ginindza TG, et al. Prevalence of and associated risk factors for high risk human papillomavirus among sexually active women. Swazil PloS One. 2017;12(1):e0170189.CrossRefPubMed Ginindza TG, et al. Prevalence of and associated risk factors for high risk human papillomavirus among sexually active women. Swazil PloS One. 2017;12(1):e0170189.CrossRefPubMed
32.
go back to reference Tounkara FK, et al. Human papillomavirus genotype distribution and factors associated among female sex workers in West Africa. PLoS ONE. 2020;15(11):e0242711.CrossRefPubMedPubMedCentral Tounkara FK, et al. Human papillomavirus genotype distribution and factors associated among female sex workers in West Africa. PLoS ONE. 2020;15(11):e0242711.CrossRefPubMedPubMedCentral
33.
go back to reference Kelly HA, et al. Epidemiology of high-risk human papillomavirus and cervical lesions in African women living with HIV/AIDS: effect of anti-retroviral therapy. Aids. 2017;31(2):273–85.CrossRefPubMed Kelly HA, et al. Epidemiology of high-risk human papillomavirus and cervical lesions in African women living with HIV/AIDS: effect of anti-retroviral therapy. Aids. 2017;31(2):273–85.CrossRefPubMed
34.
go back to reference Okunade KS et al. Prevalence and risk factors for genital high-risk human papillomavirus infection among women attending the outpatient clinics of a university teaching hospital in Lagos, Nigeria. Pan Afr Med J, 2017. 28(1). Okunade KS et al. Prevalence and risk factors for genital high-risk human papillomavirus infection among women attending the outpatient clinics of a university teaching hospital in Lagos, Nigeria. Pan Afr Med J, 2017. 28(1).
35.
go back to reference Torres-Poveda K, et al. High risk HPV infection prevalence and associated cofactors: a population-based study in female ISSSTE beneficiaries attending the HPV screening and early detection of cervical cancer program. BMC Cancer. 2019;19(1):1–12.CrossRef Torres-Poveda K, et al. High risk HPV infection prevalence and associated cofactors: a population-based study in female ISSSTE beneficiaries attending the HPV screening and early detection of cervical cancer program. BMC Cancer. 2019;19(1):1–12.CrossRef
36.
go back to reference Feng R-M et al. Role of active and passive smoking in high-risk human papillomavirus infection and cervical intraepithelial neoplasia grade 2 or worse. J Gynecologic Oncol, 2017. 28(5). Feng R-M et al. Role of active and passive smoking in high-risk human papillomavirus infection and cervical intraepithelial neoplasia grade 2 or worse. J Gynecologic Oncol, 2017. 28(5).
37.
go back to reference Mapanga W, et al. Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: a systematic review. Syst Reviews. 2018;7(1):198–8.CrossRef Mapanga W, et al. Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: a systematic review. Syst Reviews. 2018;7(1):198–8.CrossRef
38.
go back to reference Cho HW, et al. Comparison of urine, self-collected vaginal swab, and cervical swab samples for detecting human papillomavirus (HPV) with Roche Cobas HPV, Anyplex II HPV, and RealTime HR-S HPV assay. J Virol Methods. 2019;269:77–82.CrossRefPubMed Cho HW, et al. Comparison of urine, self-collected vaginal swab, and cervical swab samples for detecting human papillomavirus (HPV) with Roche Cobas HPV, Anyplex II HPV, and RealTime HR-S HPV assay. J Virol Methods. 2019;269:77–82.CrossRefPubMed
39.
go back to reference Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2536–45.CrossRefPubMedPubMedCentral Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2536–45.CrossRefPubMedPubMedCentral
Metadata
Title
Prevalence of genital high-risk human papillomavirus infections and associated factors among women living with human immunodeficiency virus in Uganda
Authors
Harriet Nakigozi
Rawlance Ndejjo
William Bazeyo
Annet Nabaggala
Caroline Achola
Moses Iga
Simeon Kalyesubula
Ben Kanamwangi
Gerald Mutungi
Charles Batte
David Mukunya
Lawrence Sserwanga
Godfrey Gemageine
Charles Akiya Oyoo
Susan Nabadda
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11928-0

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine